NKGen Biotech Net Tangible Assets

The latest net tangible assets for NKGN is $-50M as of March 2025. That compares with $-45M in the prior-year period — down 12.7% year over year. Investors often review this figure alongside NKGen Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, NKGN's net tangible assets moved from $-45M to $-50M — a 12.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in NKGen Biotech's operating scale or balance-sheet position.

A net tangible assets figure of $-50M for NKGN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NKGN's net tangible assets ($-50M), review year-over-year change from $-45M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.